Last reviewed · How we verify
AMDC-USR (iltamiocel)
AMDC-USR (iltamiocel) is an autologous skeletal myoblast cell therapy that regenerates damaged heart muscle tissue following myocardial infarction.
AMDC-USR (iltamiocel) is an autologous skeletal myoblast cell therapy that regenerates damaged heart muscle tissue following myocardial infarction. Used for Acute myocardial infarction with left ventricular dysfunction.
At a glance
| Generic name | AMDC-USR (iltamiocel) |
|---|---|
| Sponsor | Cook MyoSite |
| Drug class | Autologous cell therapy |
| Modality | Biologic |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Iltamiocel consists of patient-derived skeletal myoblasts that are expanded ex vivo and then injected directly into the scarred myocardium post-infarction. The cells differentiate and integrate into the damaged tissue, promoting structural repair, improving ventricular function, and reducing adverse remodeling. This cell-based approach aims to restore contractile function and prevent progression to heart failure.
Approved indications
- Acute myocardial infarction with left ventricular dysfunction
Common side effects
- Injection-site complications
- Arrhythmias
- Infection
Key clinical trials
- Autologous Muscle Derived Cells Compared to Placebo for Urinary Sphincter Repair in Post-surgical Female Stress Incontinence (PHASE3)
- Autologous Muscle Derived Cells for Female Urinary Sphincter Repair (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AMDC-USR (iltamiocel) CI brief — competitive landscape report
- AMDC-USR (iltamiocel) updates RSS · CI watch RSS
- Cook MyoSite portfolio CI